This miRNA may influence AD pathology by reducing Aβ clearance through the downregulation of FGF2 [83] and by interacting with critical genes associated with neurodegeneration and protein aggregation, including BACE1, GSK3β, MAPT, and PSEN1. The gene discussed is MAPT; the disease is Alzheimer disease.